Zobrazeno 1 - 10
of 346
pro vyhledávání: '"Pär Stattin"'
Publikováno v:
International Journal of Cancer. 151:1925-1934
Androgen deprivation therapy (ADT) has been hypothesized to protect against COVID-19, but previous observational studies of men with prostate cancer on ADT have been inconsistent regarding mortality risk from coronavirus disease 2019 (COVID-19). Usin
Autor:
Tiago M. Bonde, Marcus Westerberg, Markus Aly, Martin Eklund, Jan Adolfsson, Anna Bill-Axelson, Hans Garmo, Pär Stattin, David Robinson
Publikováno v:
Scandinavian Journal of Urology. 56:169-175
Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death by use of clinical variables at Pca diagnosis and PSA levels after start of gonadotropin-releasing hormone agonists (GnRH) in men with non-metastatic c
Autor:
Charlotte Alverbratt, Hanna Vikman, Marie Hjälm Eriksson, Pär Stattin, Ingela Franck Lissbrant
Publikováno v:
Scandinavian Journal of Urology. 56:95-101
Background Patients with advanced prostate cancer (PCa) typically undergo numerous lines of treatment leading to large amounts of information in Electronic Health Records (EHRs). The Patient-overview Prostate Cancer (PPC) presents clinical informatio
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-9 (2022)
BMC Urology
BMC Urology
Background: Epidemiological data on anticoagulation for venous thromboembolism (VTE) in prostate cancer are sparse. We aimed to investigate associations between anticoagulation duration and risks of VTE recurrence after treatment cessation and major
Autor:
Eugenio, Ventimiglia, Anna, Bill-Axelson, Ola, Bratt, Francesco, Montorsi, Pär, Stattin, Hans, Garmo
Publikováno v:
JAMA network open. 5(9)
The long-term outcomes among men with prostate cancer (PC) whose disease is managed with active surveillance (AS) remains unknown.To develop a simulation model with a 30-year follow-up for men with PC managed with AS.In this cohort study, a state tra
Autor:
Pär, Stattin
Publikováno v:
Scandinavian journal of urology. 56(4)
Autor:
E. Lin, Hans Garmo, Mieke Van Hemelrijck, Björn Zethelius, Pär Stattin, Emil Hagström, Jan Adolfsson, Danielle Crawley
Publikováno v:
JAMA network open. 5(8)
IMPORTANCE Men with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Meanwhile, gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer (PCa) are associated with increased risk of CVD. OBJECTIVE To evaluate the a
Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study
Autor:
Karin Braide, Jon Kindblom, Camilla Thellenberg Karlsson, Pär Stattin, Jonas Hugosson, Marianne Månsson
Publikováno v:
BJU internationalReferences. 130(6)
To estimate the long-term risks of severe late toxicities for radiation therapy (RT) following radical prostatectomy (RP) in an unselected nationwide cohort, as severe side-effects are rare but may occur years later.The study population comprised all
Autor:
Johan Syrjä, Mats Lambe, David Robinson, Irma Fredriksson, Pär Stattin, Rolf Gedeborg, Malin Sund, Hans Garmo, Anna Plym, Lars Holmberg
Publikováno v:
Epidemiology. 32:607-615
Background The ability to account for comorbidity when estimating survival in a population diagnosed with cancer could be improved by using a drug comorbidity index based on filled drug prescriptions. Methods We created a drug comorbidity index from
Autor:
Tanja Stocks, Sylvia H J Jochems, Marju Orho-Melander, Christel Häggström, Angela M. Wood, Pär Stattin
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2885-2896 (2021)
Cancer Medicine
Cancer Medicine
We recently found a negative association between body mass index (BMI) and the risk of localised prostate cancer (PCa), no association with advanced PCa, and a positive association with PCa‐specific mortality. In a 15% subpopulation of that study,